{"pmid":32435791,"title":"Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.","text":["Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.","Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro EC50/EC90 values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.","Clin Infect Dis","Fan, Jianghong","Zhang, Xinyuan","Liu, Jiang","Yang, Yuching","Zheng, Nan","Liu, Qi","Bergman, Kimberly","Reynolds, Kellie","Huang, Shiew-Mei","Zhu, Hao","Wang, Yaning","32435791"],"abstract":["Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro EC50/EC90 values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration."],"journal":"Clin Infect Dis","authors":["Fan, Jianghong","Zhang, Xinyuan","Liu, Jiang","Yang, Yuching","Zheng, Nan","Liu, Qi","Bergman, Kimberly","Reynolds, Kellie","Huang, Shiew-Mei","Zhu, Hao","Wang, Yaning"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435791","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/cid/ciaa623","keywords":["covid-19","hydroxychloroquine","sars-cov-2","antiviral activity"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667521393846124545,"score":9.490897,"similar":[{"pmid":32438446,"title":"Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.","text":["Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.","There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, EC90 values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC90 ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC90 ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (Kp Ulung ) was also simulated to derive a lung Cmax/EC50 as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50 . Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.","Clin Pharmacol Ther","Arshad, Usman","Pertinez, Henry","Box, Helen","Tatham, Lee","Rajoli, Rajith Kr","Curley, Paul","Neary, Megan","Sharp, Joanne","Liptrott, Neill J","Valentijn, Anthony","David, Christopher","Rannard, Steve P","O'Neill, Paul M","Aljayyoussi, Ghaith","Pennington, Shaun","Ward, Stephen A","Hill, Andrew","Back, David J","Khoo, Saye H","Bray, Patrick G","Biagini, Giancarlo A","Owen, Andrew","32438446"],"abstract":["There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2. However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, EC90 values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentrations (Cmax) at an approved dose in humans (Cmax/EC90 ratio). Only 14 of the 56 analysed drugs achieved a Cmax/EC90 ratio above 1. A more in-depth assessment demonstrated that only nitazoxanide, nelfinavir, tipranavir (ritonavir-boosted) and sulfadoxine achieved plasma concentrations above their reported anti-SARS-CoV-2 activity across their entire approved dosing interval. An unbound lung to plasma tissue partition coefficient (Kp Ulung ) was also simulated to derive a lung Cmax/EC50 as a better indicator of potential human efficacy. Hydroxychloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavir-boosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50 . Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 1.5-fold in lung, respectively. This analysis may be used to select potential candidates for further clinical testing, while deprioritising compounds unlikely to attain target concentrations for antiviral activity. Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials."],"journal":"Clin Pharmacol Ther","authors":["Arshad, Usman","Pertinez, Henry","Box, Helen","Tatham, Lee","Rajoli, Rajith Kr","Curley, Paul","Neary, Megan","Sharp, Joanne","Liptrott, Neill J","Valentijn, Anthony","David, Christopher","Rannard, Steve P","O'Neill, Paul M","Aljayyoussi, Ghaith","Pennington, Shaun","Ward, Stephen A","Hill, Andrew","Back, David J","Khoo, Saye H","Bray, Patrick G","Biagini, Giancarlo A","Owen, Andrew"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438446","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/cpt.1909","keywords":["covid-19","coronavirus","lung","pharmacokinetics","sars-cov-2"],"locations":["lung"],"e_drugs":["Ritonavir","nitazoxanide","Chloroquine","Mefloquine","Azithromycin","Nelfinavir","Ivermectin","tipranavir","Sulfadoxine","Hydroxychloroquine","Lopinavir","Atazanavir Sulfate"],"topics":["Treatment"],"weight":1,"_version_":1667521393853464576,"score":246.06944},{"pmid":32150618,"pmcid":"PMC7108130","title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 muM) was found to be more potent than chloroquine (EC50=5.47 muM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.","Clin Infect Dis","Yao, Xueting","Ye, Fei","Zhang, Miao","Cui, Cheng","Huang, Baoying","Niu, Peihua","Liu, Xu","Zhao, Li","Dong, Erdan","Song, Chunli","Zhan, Siyan","Lu, Roujian","Li, Haiyan","Tan, Wenjie","Liu, Dongyang","32150618"],"abstract":["BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 muM) was found to be more potent than chloroquine (EC50=5.47 muM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro."],"journal":"Clin Infect Dis","authors":["Yao, Xueting","Ye, Fei","Zhang, Miao","Cui, Cheng","Huang, Baoying","Niu, Peihua","Liu, Xu","Zhao, Li","Dong, Erdan","Song, Chunli","Zhan, Siyan","Lu, Roujian","Li, Haiyan","Tan, Wenjie","Liu, Dongyang"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32150618","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1093/cid/ciaa237","keywords":["chloroquine","hydroxychloroquine","sars-cov-2"],"link_comment_in":"32241791","locations":["Wuhan","China","PBPK","PBPK"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","Chloroquine","chloroquine diphosphate"],"topics":["Treatment"],"weight":1,"_version_":1666138492713828352,"score":231.96333},{"pmid":32460458,"title":"In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.","text":["In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.","Background/Aims: As the coronavirus disease-2019 global pandemic progresses, screening of antiviral agents effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed. In addition, considering the viral load kinetics of SARS-CoV-2, which peaks early in the illness, and the massive burden of the disease, which may increase in the near future, identifying well-tolerated oral antivirals becomes increasingly important. We examined the in vitro activity of lopinavir/ritonavir and hydroxychloroquine on SARS-CoV-2, at concentrations which can be used to treat coronavirus-19 patients with little concern of toxicity. Methods: Lopinavir/ritonavir (7/1.75 mug/mL), hydroxychloroquine base (1 or 2 mug/mL), or a combination thereof were administered 1 hour after the inoculation of SARS-CoV-2 to Vero cells at a multiplicity of infection of 0.05. We examined cytopathic effects of virus 48 hours after administration of the respective treatments and measured viral loads at three time points (0, 24, and 48 hours post-treatment) by quantitative real-time reverse-transcription polymerase chain reaction, and compared the results obtained from the different antiviral regimens tested. Results: The severity of cytopathic effects was lower in lopinavir/ritonavir-treated cells, and viral load was significantly reduced in this group compared with the control group (p < 0.001). However, hydroxychloroquine did not show significant inhibitory effects on anti-SARS-CoV-2-mediated cytotoxicity or on viral load at either concentration. Conclusions: Lopinavir/ritonavir showed significant inhibitory effects on SARS-CoV-2 in vitro at its usual plasma concentration. However, the in vitro antiviral activity of hydroxychloroquine at concentrations commonly used in humans was minimal, whether used alone or in combination with lopinavir/ritonavir.","Korean J Intern Med","Kang, Chang Kyung","Seong, Moon-Woo","Choi, Su-Jin","Kim, Taek Soo","Choe, Pyoeng Gyun","Song, Sang Hoon","Kim, Nam-Joong","Park, Wan Beom","Oh, Myoung-Don","32460458"],"abstract":["Background/Aims: As the coronavirus disease-2019 global pandemic progresses, screening of antiviral agents effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed. In addition, considering the viral load kinetics of SARS-CoV-2, which peaks early in the illness, and the massive burden of the disease, which may increase in the near future, identifying well-tolerated oral antivirals becomes increasingly important. We examined the in vitro activity of lopinavir/ritonavir and hydroxychloroquine on SARS-CoV-2, at concentrations which can be used to treat coronavirus-19 patients with little concern of toxicity. Methods: Lopinavir/ritonavir (7/1.75 mug/mL), hydroxychloroquine base (1 or 2 mug/mL), or a combination thereof were administered 1 hour after the inoculation of SARS-CoV-2 to Vero cells at a multiplicity of infection of 0.05. We examined cytopathic effects of virus 48 hours after administration of the respective treatments and measured viral loads at three time points (0, 24, and 48 hours post-treatment) by quantitative real-time reverse-transcription polymerase chain reaction, and compared the results obtained from the different antiviral regimens tested. Results: The severity of cytopathic effects was lower in lopinavir/ritonavir-treated cells, and viral load was significantly reduced in this group compared with the control group (p < 0.001). However, hydroxychloroquine did not show significant inhibitory effects on anti-SARS-CoV-2-mediated cytotoxicity or on viral load at either concentration. Conclusions: Lopinavir/ritonavir showed significant inhibitory effects on SARS-CoV-2 in vitro at its usual plasma concentration. However, the in vitro antiviral activity of hydroxychloroquine at concentrations commonly used in humans was minimal, whether used alone or in combination with lopinavir/ritonavir."],"journal":"Korean J Intern Med","authors":["Kang, Chang Kyung","Seong, Moon-Woo","Choi, Su-Jin","Kim, Taek Soo","Choe, Pyoeng Gyun","Song, Sang Hoon","Kim, Nam-Joong","Park, Wan Beom","Oh, Myoung-Don"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32460458","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3904/kjim.2020.157","keywords":["covid-19","hydroxychloroquine","in vitro techniques","lopinavir/ritonavir","severe acute respiratory syndrome coronavirus 2"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1668079521432076288,"score":210.95602},{"pmid":32344177,"pmcid":"PMC7182748","title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.","text":["In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.","Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.","Microb Pathog","Andreani, Julien","Le Bideau, Marion","Duflot, Isabelle","Jardot, Priscilla","Rolland, Clara","Boxberger, Manon","Wurtz, Nathalie","Rolain, Jean-Marc","Colson, Philippe","La Scola, Bernard","Raoult, Didier","32344177"],"abstract":["Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung."],"journal":"Microb Pathog","authors":["Andreani, Julien","Le Bideau, Marion","Duflot, Isabelle","Jardot, Priscilla","Rolland, Clara","Boxberger, Manon","Wurtz, Nathalie","Rolain, Jean-Marc","Colson, Philippe","La Scola, Bernard","Raoult, Didier"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344177","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.micpath.2020.104228","keywords":["2019-ncov","azithromycin","covid-19","hydroxychloroquine","sars-cov-2","vero e6"],"locations":["vivo"],"e_drugs":["Hydroxychloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666138495074172928,"score":201.10388},{"pmid":32344449,"title":"Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.","text":["Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness.","Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS-CoV-2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50 ) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in >50% of subjects at steady state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or three times weekly is required. In an exposure driven post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in >50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy.","Clin Pharmacol Ther","Al-Kofahi, Mahmoud","Jacobson, Pamala","Boulware, David R","Matas, Arthur","Kandaswamy, Raja","Jaber, Mutaz M","Rajasingham, Radha","Young, Jo-Anne H","Nicol, Melanie R","32344449"],"abstract":["Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS-CoV-2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC50 ) and to help guide researchers in dose-selection for COVID-19 prophylactic studies. To maintain weekly troughs above EC50 in >50% of subjects at steady state in a pre-exposure prophylaxis setting, an 800 mg loading dose followed by 400 mg twice or three times weekly is required. In an exposure driven post-exposure prophylaxis setting, 800 mg loading dose followed in 6 hours by 600 mg, then 600 mg daily for 4 more days achieved daily troughs above EC50 in >50% subjects. These doses are higher than recommended for malaria chemoprophylaxis, and clinical trials are needed to establish safety and efficacy."],"journal":"Clin Pharmacol Ther","authors":["Al-Kofahi, Mahmoud","Jacobson, Pamala","Boulware, David R","Matas, Arthur","Kandaswamy, Raja","Jaber, Mutaz M","Rajasingham, Radha","Young, Jo-Anne H","Nicol, Melanie R"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344449","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1874","keywords":["covid-19","sars-cov-2","hydroxychloroquine","pharmacokinetics"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138495828099072,"score":193.79474}]}